المؤلفون: Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., Chanchlani, N., Nice, R., McDonald, T. J., Lamb, C. A., Sebastian, S., Kok, K., Lees, C. W., Hart, A. L., Pollok, R. C., Boyton, R. J., Altmann, D. M., Pollock, K. M., Goodhand, J. R., Kennedy, N. A., Ahmad, T., Powell, N.

مصطلحات موضوعية: Humans, Female, Male, Middle Aged, COVID-19 Vaccines, SARS-CoV-2, Infliximab/therapeutic use, COVID-19/prevention & control, Prospective Studies, Tumor Necrosis Factor Inhibitors/therapeutic use, Inflammatory Bowel Diseases/drug therapy, Antibodies, Neutralizing, Breakthrough Infections

العلاقة: Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi:10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5.; The lancet. Gastroenterology & hepatology; PMC9757903 Ferring. SS reports grants from Takeda, Tillots Pharma, Janssen, and Amgen; speaker honoraria from Janssen, Tillotts Pharma, Amgen, AbbVie, and Ferring; personal fees from Takeda, Janssen, and Tillots Pharma; and serving as an advisory board member for Takeda. CAL declares research support or fees for development and delivery of non-promotional education from Janssen, Takeda, AbbVie, AstraZeneca, Eli Lilly, Orion, Pfizer, Roche, Sanofi Aventis, Ferring, Dr Falk, UCB, Biogen, and Genentech. ALH has served as consultant, advisory board member, or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Ferring, Galapagos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda and serves on the global steering committee for Genentech. KK reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen and Ferring; support for attending meetings or travel from Janssen and Takeda; and participation on a data safety monitoring board or advisory board for Janssen and PredictImmune. CWL reports personal consulting fees from Galapagos, AbbVie, Takeda, Pfizer, Janssen, and Iterative Scopes; institutional consulting fees from Trellus Health; and personal fees and support for attending meetings from Galapagos, AbbVie, Takeda, Pfizer, Janssen, GSK, Gilead, Fresenius Kabi, Ferring, and Dr Falk. JRG reports grants from F Hoffmann-La Roche, Biogen, Celltrion Healthcare, Takeda, and Galapagos during the study. KMP is chief, principal, or co-investigator for vaccine clinical trials and experimental medicine studies (NCT05007275, NCT04753892, EudraCT 2020-001646-20, NCT04400838, NCT04324606, EudraCT 2017-004610-26, NCT03970993, and NCT03816137), is a member of the data safety monitoring board for two vaccine trials (NCT05249829 and NCT05575492), has received a fee for speaking from Seqirus and Sanofi Pasteur, and has research funding from the Chan Zuckerberg Initiative, the UK Medical research Council/UK Research and Innovation, the Vaccine Task Force, and National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC), outside the submitted work. NAK reports grants from F Hoffmann-La Roche AG, Biogen, Celltrion Healthcare, Takeda, and Galapagos during the conduct of the study; grants and non-financial support from AbbVie, MSD, Napp, Pfizer, Celgene, and Pharmacosmos; grants and personal fees from Celltrion; personal fees and non-financial support from Janssen, Tillots Pharma and Dr Falk; and personal fees from Allergan, Ferring, Pharmacosmos, Takeda, Amgen, Bristol-Myers Squibb, and Mylan, outside the submitted work. TA reports grants from F Hoffmann-La Roche AG, Biogen, Celltrion Healthcare, Takeda, Galapagos, and Crohn's and Colitis UK during the conduct of the study; payment for educational events for Takeda; and serving as medical advisor to Crohn's and Colitis UK, outside of the submitted work. NP reports grants from F Hoffmann-La Roche AG, Biogen, Celltrion Healthcare, Takeda, Galapagos, and Crohn's and Colitis UK during the conduct of the study; research grants from Bristol Myers Squibb and Pfizer; and personal fees from Takeda, Janssen, Pfizer, Galapagos, Bristol-Myers Squibb, AbbVie, Roche, Lilly, Allergan, Celgene, and Astra Zeneca outside the submitted work; and has served as a speaker or advisory board member for AbbVie, Allergan, Bristol-Myers Squibb, Celgene, Dr Falk, Galapagos, AstraZeneca, and Vifor Pharma. SL is supported by a Wellcome GW4-CAT fellowship. NC acknowledges support from Crohn's and Colitis UK. CAL acknowledges support from the NIHR Newcastle BRC and the support of the Programmed Investigation Unit at Royal Victoria Infirmary, Newcastle upon Tyne. CWL is funded by a UKRI Future Leaders Fellowship. NP is supported by the NIHR Imperial BRC. All other authors declare no competing interests.; https://hdl.handle.net/11287/622865Test

الإتاحة: https://doi.org/10.1016/s2468-1253Test(22)00389-2
https://doi.org/10.1016/S2468-1253Test(22)00389-2
https://hdl.handle.net/11287/622865Test

المؤلفون: Manisty, C, Treibel, TA, Jensen, M, Semper, A, Joy, G, Gupta, RK, Cutino-Moguel, T, Andiapen, M, Jones, J, Taylor, S, Otter, A, Pade, C, Gibbons, J, Lee, J, Bacon, J, Thomas, S, Moon, C, Jones, M, Williams, D, Lambourne, J, Fontana, M, Altmann, DM, Boyton, R, Maini, M, McKnight, A, Chain, B, Noursadeghi, M, Moon, JC

المصدر: EBioMedicine. 65:103259

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:146245886Test

المؤلفون: Liu, Z., Alexander, J. L., Eng, K. Y., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., Constable, L., Seoane, R. C., Bewshea, C., Nice, R., D'Mello, A., Jones, G. R., Balarajah, S., Fiorentino, F., Sebastian, S., Irving, P. M., Hicks, L. C., Williams, H. R. T., Kent, A. J., Linger, R., Parkes, M., Kok, K., Patel, K. V., Teare, J. P., Altmann, D. M., Boyton, R. J., Hart, A. L., Lees, C. W., Goodhand, J. R., Kennedy, N. A., Pollock, K. M., Ahmad, T., Powell, N.

مصطلحات موضوعية: JAK-inhibitor, anti-TNF, humoral immunity, immunisation

العلاقة: Liu Z, Alexander JL, Eng KY, Ibraheim H, Anandabaskaran S, Saifuddin A, et al. Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib. J Crohns Colitis. 2023.; Journal of Crohn's and colitis; https://hdl.handle.net/11287/623091Test

الإتاحة: https://doi.org/10.1093/ecco-jcc/jjad182Test
https://hdl.handle.net/11287/623091Test

المؤلفون: Kennedy, N. A., Janjua, M., Chanchlani, N., Lin, S., Bewshea, C., Nice, R., McDonald, T. J., Auckland, C., Harries, L. W., Davies, M., Michell, S., Kok, K. B., Lamb, C. A., Smith, P. J., Hart, A. L., Pollok, R. C., Lees, C. W., Boyton, R. J., Altmann, D. M., Sebastian, S., Powell, N., Goodhand, J. R., Ahmad, T.

مصطلحات موضوعية: Covid-19, biological, immunosuppression, inflammatory bowel disease, infliximab, vaccination, vedolizumab, Biogen, grants fro

العلاقة: https://gut.bmj.com/lookup/pmidlookup?view=long&pmid=35902214Test; Gut. 2022 Jul 28:gutjnl-2022-327570. doi:10.1136/gutjnl-2022-327570.; https://rde.dspace-express.com/handle/11287/622664Test; Gut

الإتاحة: https://doi.org/10.1136/gutjnl-2022-327570Test
https://rde.dspace-express.com/handle/11287/622664Test

المؤلفون: Alexander, J. L., Liu, Z., Muñoz Sandoval, D., Reynolds, C., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., Castro Seoane, R., Anand, N., Nice, R., Bewshea, C., D'Mello, A., Constable, L., Jones, G. R., Balarajah, S., Fiorentino, F., Sebastian, S., Irving, P. M., Hicks, L. C., Williams, H. R. T., Kent, A. J., Linger, R., Parkes, M., Kok, K., Patel, K. V., Teare, J. P., Altmann, D. M., Goodhand, J. R., Hart, A. L., Lees, C. W., Boyton, R. J., Kennedy, N. A., Ahmad, T., Powell, N.

العلاقة: https://linkinghub.elsevier.com/retrieve/pii/S2468-1253Test(22)00005-X; Lancet Gastroenterol Hepatol. 2022 Sep 8:S2468-1253(22)00274-6. doi:10.1016/S2468-1253(22)00274-6.; https://rde.dspace-express.com/handle/11287/622614Test; The lancet. Gastroenterology & hepatology; PMC9458592 accommodation and travel to BSG 2019, outside the submitted work. NAK reports grants from AbbVie, Biogen, Celgene, Celtrion, Galapagos, MSD, Napp, Pfizer, Pharmacosmos, Roche, and Takeda; consulting fees from Amgen, Bristol Myers Squibb, Falk, Janssen, Mylan, Pharmacosmos, Galapagos, Takeda, and Tillotts; personal fees from Allergan, Celltrion, Falk, Ferring, Janssen, Pharmacosmos, Takeda, Tilllotts, and Galapagos; and support for attending meetings from AbbVie, Falk, and Janssen, outside the submitted work. AS has received travel expense support from Janssen. SS reports grants from Takeda, AbbVie, Tillots Pharma, Janssen, Pfizer, and Biogen; and personal fees from Takeda, AbbVie, Janssen, Pharmacocosmos, Biogen, Pfizer, Tillots Pharma, and Falk Pharma, outside the submitted work. ALH reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, AstraZeneca, Atlantic, Bristol Myers Squibb, Celltrion, Falk, Galapogos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda; global steering committee for Genentech; support for attending meetings from AbbVie, Takeda, and Janssen; and participation on a data safety monitoring board or advisory board for AbbVie, AstraZeneca, Atlantic, Bristol Myers Squibb, Galapogos, Janssen, Pfizer, and Takeda. PMI reports grants and personal fees from Celltrion, Takeda, Pfizer, Galapagos; grants from MSD; and personal fees from Gilead, AbbVie, Janssen, Bristol Myers Squibb, Lilly, and Arena, outside the submitted work. MP receives unrestricted educational grants from Pfizer for genetic analyses to support the IBD BioResource, and speaker fees from Janssen. GRJ has received grants from Wellcome Trust and ECCO; speaker fees from Takeda, Ferring, and Janssen; and support for attending meetings or travel from Ferring. KK reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen and Ferring; support for attending meetings or travel from Janssen and Takeda; and participation on a data safety monitoring board or advisory board for Janssen and Predict Immune. SB reports funding from Ferring and Dr Falk for accommodation, travel, and meeting fees. KVP reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Dr Falk, Janssen, PreddictImmune, and Takeda; support for attending meetings or travel from AbbVie, Ferring, Janssen, and Tillots; and participation on a data safety monitoring board or advisory board for AbbVie, Galapagos, and Janssen. AJK reports consulting fees from Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer and Takeda; support for attending meetings or travel from Janssen, Tillots, and Norgine; and participation on a data safety monitoring board or advisory board for AbbVie. LCH reports support for attending meetings or travel from AbbVie. CWL reports a Future Leaders Fellow award from UKRI; personal consulting fees from Galapagos, AbbVie, Takeda, Pfizer, Janssen, and Iterative Scopes; institutional consulting fees from Trellus Health; personal fees from Galapagos, AbbVie, Takeda, Pfizer, Janssen, GSK, Gilead, Fresnius Kabi, Ferring, and Dr Falk; and support for attending meetings from Galapagos, AbbVie, Takeda, Pfizer, Janssen, GSK, Gilead, Fresnius Kabi, Ferring, and Dr Falk. RJB and DMA are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. JRG reports grants from F Hoffmann-La Roche AG; grants from Biogen, Celltrion Healthcare, and Galapagos NV; and non-financial support from Immundiagnostik, during the conduct of the study. TA reports grant funding from Pfizer to his institution to deliver this study; grants from Celltrion, Roche, Takeda, Biogen, and Galapagos; and honoraria for lectures from Takeda and Roche, outside the submitted work. Financial support for the VIP study was provided as a research grant by Pfizer and NP is the principal investigator on this grant. NP has received research grants from Bristol Myers Squibb outside the submitted work; reports personal fees from Takeda, Janssen, Pfizer, Bristol Myers Squibb, AbbVie, Roche, Lilly, Allergan, and Celgene, outside the submitted work; and has served as a speaker or advisory board member for AbbVie, Allergan, Bristol Myers Squibb, Celgene, Falk, Ferring, Janssen, Pfizer, Tillotts, Takeda, and Vifor Pharma. All other authors declare no competing interests.

الإتاحة: https://doi.org/10.1016/s2468-1253Test(22)00274-6
https://doi.org/10.1016/S2468-1253Test(22)00274-6
https://rde.dspace-express.com/handle/11287/622614Test

المؤلفون: Alexander, J. L., Kennedy, N. A., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., Castro Seoane, R., Liu, Z., Nice, R., Bewshea, C., D'Mello, A., Constable, L., Jones, G. R., Balarajah, S., Fiorentino, F., Sebastian, S., Irving, P. M., Hicks, L. C., Williams, H. R. T., Kent, A. J., Linger, R., Parkes, M., Kok, K., Patel, K. V., Teare, J. P., Altmann, D. M., Boyton, R. J., Goodhand, J. R., Hart, A. L., Lees, C. W., Ahmad, T., Powell, N.

مصطلحات موضوعية: Adolescent, Adult, Antibody Formation, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines, Case-Control Studies, ChAdOx1 nCoV-19, Humans, Inflammatory Bowel Diseases/drug therapy, Prospective Studies, SARS-CoV-2

العلاقة: https://linkinghub.elsevier.com/retrieve/pii/S2468-1253Test(22)00005-X; Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-352. doi:10.1016/S2468-1253(22)00005-X. Epub 2022 Feb 4.; https://rde.dspace-express.com/handle/11287/622401Test; The lancet. Gastroenterology & hepatology; PMC8813209

الإتاحة: https://doi.org/10.1016/s2468-1253Test(22)00005-x
https://doi.org/10.1016/S2468-1253Test(22)00005-X
https://rde.dspace-express.com/handle/11287/622401Test

المؤلفون: Liu, Z, Le, K, Zhou, X, Alexander, J, Lin, S, Bewshea, C, Chanchlani, N, Nice, R, McDonald, T, Lamb, C, Sebastian, S, Kok, K, Lees, C, Hart, A, Pollok, R, Boyton, R, Altmann, DM, Pollock, KM, Goodhand, J, Kennedy, N, Ahmad, T, Powell, N

المصدر: 156 ; 145

العلاقة: The Lancet Gastroenterology & Hepatology; http://hdl.handle.net/10044/1/100318Test

الإتاحة: https://doi.org/10.1016/S2468-1253Test(22)00389-2
http://hdl.handle.net/10044/1/100318Test

المؤلفون: Alexander, J, Kennedy, N, Ibraheim, H, Anandabaskaran, S, Saifuddin, A, Castro Seoane, R, Liu, Z, Nice, R, Bewshea, C, D’Mello, A, Constable, L, Jones, G R, Balarajah, S, Fiorentino, F, Sebastian, S, Irving, P M, Hicks, L, Williams, H, Kent, A, Linger, R, King, R, Parkes, M, Kok, K, Patel, K, Altmann, D, Boyton, R, Goodhand, J, Hart, A, Lees, C, Ahmad, T, Powell, N

المصدر: Journal of Crohn's and Colitis ; volume 16, issue Supplement_1, page i022-i023 ; ISSN 1873-9946 1876-4479

مصطلحات موضوعية: Gastroenterology, General Medicine

الإتاحة: https://doi.org/10.1093/ecco-jcc/jjab232.020Test
https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i022/42250252/jjab232.020.pdfTest

المؤلفون: Lin, S, Kennedy, N A, Saifuddin, A, Muñoz Sandoval, D, Reynolds, C J, Seoane, R C, Kottoor, S H, Pieper, F P, Lin, K M, Butler, D K, Chanchlani, N, Nice, R, Chee, D, Bewshea, C, Janjua, M, McDonald, T J, Sebastian, S, Alexander, J L, Constable, L, Lee, J C, Murray, C D, Hart, A L, Irving, P M, Jones, G R, Kok, K B, Lamb, C A, Lees, C W, Altmann, D M, Boyton, R J, Goodhand, J R, Powell, N, Ahmad, T

المصدر: Journal of Crohn's and Colitis ; volume 16, issue Supplement_1, page i023-i025 ; ISSN 1873-9946 1876-4479

مصطلحات موضوعية: Gastroenterology, General Medicine

الإتاحة: https://doi.org/10.1093/ecco-jcc/jjab232.021Test
https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i023/42250112/jjab232.021.pdfTest

المؤلفون: Pinato D. J., Murray S. M., Forner A., Kaneko T., Fessas P., Toniutto P., Minguez B., Cacciato V., Avellini C., Diaz A., Boyton R. J., Altmann D. M., Goldin R. D., Akarca A. U., Marafioti T., Mauri F. A., Casagrande E., Grillo F., Giannini E., Bhoori S., Mazzaferro V.

المساهمون: Pinato, D. J., Murray, S. M., Forner, A., Kaneko, T., Fessas, P., Toniutto, P., Minguez, B., Cacciato, V., Avellini, C., Diaz, A., Boyton, R. J., Altmann, D. M., Goldin, R. D., Akarca, A. U., Marafioti, T., Mauri, F. A., Casagrande, E., Grillo, F., Giannini, E., Bhoori, S., Mazzaferro, V.

مصطلحات موضوعية: immunotherapy, liver neoplasms

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000703191800004; volume:9; issue:9; firstpage:e003311; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11390/1212822Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85116606294

الإتاحة: https://doi.org/10.1136/jitc-2021-003311Test
http://hdl.handle.net/11390/1212822Test